DOCSLIB.ORG

US5358943.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

|||||||||||||| US005358943A United States Patent (19) 11 Patent Number: 5,358,943 Clark et al. (45) Date of Patent: Oct. 25, 1994 54 USE OF TETRAHYDROCORTISOL TO The Merck Index, Tenth Edition (1983). PREVENTELEVATIONS IN INTRAOCULAR Meyer, et al., “Influence of Norethynodrel with Mes PRESSURE CAUSED BY tranol on Intraocular Pressure in Glaucoma', Arch Oph CORT COSTERODS thal, vol. 75, pp. 771-773 (1966). 76 Inventors: Abbot F. Clark, 5708 Stage Line Dr., Mindel, et al., “Comparative Ocular Pressure Elevation Arlington, Tex. 76017; Aaron L. by Medrysone, Flourometholone, and Dexamethasone Southren, 107 Grandview Ave., Phosphate', Archives of Ophthalmology, vol. 98, pp. Monsey, N.Y. 10952 1577-1578 (1980). Southren, A. Louis, et al., “Intraocular Hypotensive 21 Appl. No.: 12,181 Effect of a Topically Applied Cortisol Metabolite: 3a, 22 Filed: Feb. 2, 1993 5p3-Tetrahydrocortisol”, Investigative Ophthalmology & Visual Science, vol. 28, pp. 901-903 (May 1987). Related U.S. Application Data Treister, et al., “Intraocular Pressure and Outflow Fa cility”, Arch Ophthal, vol. 83, pp. 311-318 (1970). 63 Continuation of Ser. No. 399,349, Aug. 28, 1989, aban Medline Abstract 87193644 (1987), Southren, et al. doned, which is a continuation of Ser. No. 139,227, Danhaive, et al., "Binding of Glucocorticoid Antago Dec. 29, 1987, abandoned. nists to Androgen and Glucocorticoild Hormone Re 51 Int. Cl. ...................... A61K31/56; A61K 31/33 ceptors in Rat Skeletal Muscle', J. steroid Biochem., vol. 52 U.S. C. .................................... 514/170; 514/171; 24, No. 2, pp. 481-487, 1986. 514/182, 514/914: 514/922 Primary Examiner-Zohreh Fay 58 Field of Search ............... 514/170, 171, 182,914, Attorney, Agent, or Firm-James A. Arno; Gregg C. 514/922 Brown 56 References Cited 57 ABSTRACT U.S. PATENT DOCUMENTS Pharmaceutical compositions useful in the treatment of 3,449,494 6/1969 Lerner ................................. 424/240 ophthalmic inflammation and methods of treating oph 3,474,168 10/1969 Schayer. ... 424/240 4,383,992 5/1983 Lipari........ ... 424/238 thalmic inflammation with those compositions are dis 4,617,299 10/1986 Knepper ... ... 514/1.78 closed. The compositions contain a combination of a 4,686,214 8/1987 Boltradik ... ... 514/179 glucocorticoid and tetrahydrocortisol. The tetrahy 4,863,912 9/1989 Southren ... ... 514/177 drocortisol serves to substantially prevent any signifi 4,945,089 7/1990 Clark ................................... 514/171 cant increases in intraocular pressure which might oth erwise be experienced by the patient as a side effect of FOREIGN PATENT DOCUMENTS the glucocorticoid component of the compositions. The 0250088 12/1987 European Pat. Off. therapeutic interaction of the two components there WO86/02554 5/1986 PCT Int'l Appl. fore allows the potent antiinflammatory properties of the glucocorticoids to be utilized without fear of elevat OTHER PUBLICATIONS ing intraocular pressure. A method of preventing in Cantrill, et al., “Comparison of In Vitro Potency of creases in intraocular pressure attributable to systemic Corticosteroids with Ability to Raise Intraocular Pres or topical corticosteroid therapy is also disclosed. That sure', American Journal of Ophthalmology, vol. 79, pp. method involves the administration of a pharmaceutical 1012-1016 (1975). composition containing tetrahydrocortisol to a patient Kitazawa, “Increased Intraocular Pressure Induced by receiving such therapy. Corticosteroids', American Journal of Ophthalmology, vol. 82, pp. 492-495 (1976). 12 Claims, No Drawings 5,358,943 1. 2 the invention is the provision of methods of treatment USE OF TETRAHYDROCORTESOL TO PREVENT and ophthalmic compositions useful in that therapy. ELEVATIONS IN INTRAOCULAR PRESSURE Another objective of the present invention is the CAUSED BY CORT COSTEROIDS provision of a prophylactic method of treatment 5 wherein the elevations in intraocular pressure some This is a continuation of application Ser. No. times associated with corticosteroid therapy are sub 07/399,349, filed Aug. 28, 1989 now abandoned, which stantially prevented. is a continuation of Ser. No. 07/139,227, filed Dec. 29, The foregoing objectives and other general objec 1987 now abandoned. tives of the present invention are met by the provision O of a therapy for ophthalmic inflammation wherein the BACKGROUND OF THE INVENTION elevations in intraocular pressure caused by glucocorti The present invention relates to the field of ophthal coids are substantially prevented. The therapy involves mology. More particularly, this invention relates to the the combination of a glucocorticoid with a second com treatment of inflamed ocular tissue. pound which prevents or antagonizes the intraocular Many compounds classified as glucocorticoids, such 15 pressure elevating effect of the glucocorticoid. The as dexamethasone and prednisolone, are very effective second compound is tetrahydrocortisol. It has been in the treatment of inflamed tissues, but in certain pa discovered that the intraocular pressure ("IOP”) elevat tients, these compounds cause elevations in intraocular ing effect of glucocorticoids can be eliminated without pressure. Patients who experience elevations in intraoc adversely affecting the antiinflammatory activity of the ular pressure when treated with glucocorticoids are 20 glucocorticoids. Thus, the therapy of the present inven generally referred to as "steroid responders'. The ele tion makes it possible to employ the potent topical anti vations in intraocular pressure are of particular concern inflammatory properties of the glucocorticoids without in patients who are already suffering from elevated causing any significant elevations in intraocular pres intraocular pressures, such as glaucoma patients. More Sle. 25 over, there is always a risk that the use of glucocorti DESCRIPTION OF PREFERRED coids in patients who have normal intraocular pressures EMBODIMENTS will cause elevations in pressure that result in damage to ocular tissue. Since therapy with glucocorticoids is The present invention is based on the combination of frequently long term (i.e., several days or more), there is one or more potent glucocorticoids with tetrahydrocor 30 tisol. It has been discovered that tetrahydrocortisol potential for significant damage to ocular tissue as a antagonizes the IOP elevating effect of glucocorticoids. result of prolonged elevations in intraocular pressure It was previously discovered that tetrahydrocortisol is attributable to that therapy. effective in controlling intraocular pressure; that dis The following articles may be referred to for further covery is the subject of U.S. patent application Ser. No. background information concerning the well recog 35 864,610, filed May 19, 1986, the entire contents of which nized association between ophthalmic glucocorticoid are hereby incorporated in the present specification by therapy and elevations in intraocular pressure: reference. The intraocular hypotensive effect of tet Kitazawa, “Increased Intraocular Pressure Induced by rahydrocortisol is reported by A. Louis Southren et al. Corticosteroids', American Journal of Ophthalmology, in Investigative Ophthalmology & Visual Science, Vol. 28, Vol. 82, pages 492-495 (1976); Cantrill et al., “Compari 40 pages 901-903 (May 1987); the entire contents of that son of In Vitro Potentcy of Corticosteroids with Ability report are also incorporated herein by reference. to Raise Intraocular Pressure', American Journal of It has been postulated that tetrahydrocortisol con Ophthalmology, Vol. 79, pages 1012-1016 (1975); and trols intraocular pressure by antagonizing the action of Mindel et al., “Comparative Ocular Pressure Elevation 5-alpha and/or 5-beta-dihydrocortisol, which are two by Medrysone, Fluorometholone, and Dexamethasone 45 substances that are believed to play a significant role in Phosphate', Archives of Ophthalmology, Vol. 98, pages a metabolic imbalance involving the trabecular mesh 1577-1578 (1980). work cells of the eye and, ultimately, elevations in intra One approach to solving the foregoing problems has ocular pressure. The present invention is based on the been to search for compounds which are capable of finding that tetrahydrocortisol somehow antagonizes alleviating ophthalmic inflammation without elevating 50 the IOP elevating effect of glucocorticoids. The mecha intraocular pressure. The inventions described in U.S. nism by which tetrahydrocortisol prevents or antago Pat. No. 4,686,214 and in copending U.S. patent appli nizes the IOP elevating effect of glucocorticoids is not cation Ser. No. 864,610, filed May 19, 1986, represent totally understood at this point. While applicants do not two examples of this approach. Notwithstanding the wish to be bound by any theory, one possible explana success of the therapies described in the above-cited 55 tion is that tetrahydrocortisol interferes with the action patent and patent application, there continues to be a of glucocorticoids on trabecular meshwork cells, need for still further improvements in the treatment of thereby blocking or reversing the IOP elevating effect ophthalmic inflammation, such as an improvement of the glucocorticoids. which would allow potent glucocorticoids to be uti Tetrahydrocortisol is a known compound. It has a lized to treat inflamed ocular tissue without fear of 60 molecular weight of 366.5, and an empirical formula of elevating intraocular pressure. C2H34O5. The compound is commercially available SUMMARY OF THE INVENTION and may, for example, be obtained
Recommended publications
  • Penetration of Synthetic Corticosteroids Into Human Aqueous Humour

    Penetration of Synthetic Corticosteroids Into Human Aqueous Humour

    Eye (1990) 4, 526--530 Penetration of Synthetic Corticosteroids into Human Aqueous Humour C. N. 1. McGHEE,1.3 D. G. WATSON, 3 1. M. MIDGLEY, 3 M. 1. NOBLE, 2 G. N. DUTTON, z A. I. FERNl Glasgow Summary The penetration of prednisolone acetate (1%) and fluorometholone alcohol (0.1%) into human aqueous humour following topical application was determined using the very sensitive and specific technique of Gas Chromatography with Mass Spec­ trometry (GCMS). Prednisolone acetate afforded peak mean concentrations of 669.9 ng/ml within two hours and levels of 28.6 ng/ml in aqueous humour were detected almost 24 hours post application. The peak aqueous humour level of flu­ orometholone was S.lng/ml. The results are compared and contrasted with the absorption of dexamethasone alcohol (0.1%), betamethasone sodium phosphate (0.1 %) and prednisolone sodium phosphate (0.5%) into human aqueous humour. Topical corticosteroid preparations have been prednisolone acetate (1.0%) and fluorometh­ used widely in ophthalmology since the early alone alcohol (0.1 %) (preliminary results) 1960s and over the last 10 years the choice of into the aqueous humour of patients under­ preparations has become larger and more going elective cataract surgery. varied. Unfortunately, data on the intraocular penetration of these steroids in humans has SUbjects and Methods not paralleled the expansion in the number of Patients who were scheduled to undergo rou­ available preparations; indeed until recently, tine cataract surgery were recruited to the estimation of intraocular penetration has study and informed consent was obtained in been reliant upon extrapolation of data from all cases (n=88), Patients with corneal disease animal models (see Watson et ai., 1988, for or inflammatory ocular conditions which bibliography).
  • A New Robust Technique for Testing of Glucocorticosteroids in Dogs and Horses Terry E

    A New Robust Technique for Testing of Glucocorticosteroids in Dogs and Horses Terry E

    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 2007 A new robust technique for testing of glucocorticosteroids in dogs and horses Terry E. Webster Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Veterinary Toxicology and Pharmacology Commons Recommended Citation Webster, Terry E., "A new robust technique for testing of glucocorticosteroids in dogs and horses" (2007). Retrospective Theses and Dissertations. 15029. https://lib.dr.iastate.edu/rtd/15029 This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. A new robust technique for testing of glucocorticosteroids in dogs and horses by Terry E. Webster A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Toxicology Program o f Study Committee: Walter G. Hyde, Major Professor Steve Ensley Thomas Isenhart Iowa State University Ames, Iowa 2007 Copyright © Terry Edward Webster, 2007. All rights reserved UMI Number: 1446027 Copyright 2007 by Webster, Terry E. All rights reserved. UMI Microform 1446027 Copyright 2007 by ProQuest Information and Learning Company. All rights reserved. This microform edition is protected against unauthorized copying under Title 17, United States Code. ProQuest Information and Learning Company 300 North Zeeb Road P.O. Box 1346 Ann Arbor, MI 48106-1346 ii DEDICATION I want to dedicate this project to my wife, Jackie, and my children, Shauna, Luke and Jake for their patience and understanding without which this project would not have been possible.
  • Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate

    Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate

    Steroid Use in Prednisone Allergy Abby Shuck, PharmD candidate 2015 University of Findlay If a patient has an allergy to prednisone and methylprednisolone, what (if any) other corticosteroid can the patient use to avoid an allergic reaction? Corticosteroids very rarely cause allergic reactions in patients that receive them. Since corticosteroids are typically used to treat severe allergic reactions and anaphylaxis, it seems unlikely that these drugs could actually induce an allergic reaction of their own. However, between 0.5-5% of people have reported any sort of reaction to a corticosteroid that they have received.1 Corticosteroids can cause anything from minor skin irritations to full blown anaphylactic shock. Worsening of allergic symptoms during corticosteroid treatment may not always mean that the patient has failed treatment, although it may appear to be so.2,3 There are essentially four classes of corticosteroids: Class A, hydrocortisone-type, Class B, triamcinolone acetonide type, Class C, betamethasone type, and Class D, hydrocortisone-17-butyrate and clobetasone-17-butyrate type. Major* corticosteroids in Class A include cortisone, hydrocortisone, methylprednisolone, prednisolone, and prednisone. Major* corticosteroids in Class B include budesonide, fluocinolone, and triamcinolone. Major* corticosteroids in Class C include beclomethasone and dexamethasone. Finally, major* corticosteroids in Class D include betamethasone, fluticasone, and mometasone.4,5 Class D was later subdivided into Class D1 and D2 depending on the presence or 5,6 absence of a C16 methyl substitution and/or halogenation on C9 of the steroid B-ring. It is often hard to determine what exactly a patient is allergic to if they experience a reaction to a corticosteroid.
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1

    Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1

    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
  • Sir, Mistaken Eye Drops and Subsequent Instillation of Superglue

    Sir, Mistaken Eye Drops and Subsequent Instillation of Superglue

    Sir, in susceptible (steroid-responsive) patients. Rimexolone Mistaken eye drops and subsequent instillation of 1 % ophthalmic suspension is a recently developed superglue topical corticosteroid with effective anti-inflammatory z 3 A 60-year-old man presented himself to the casualty properties as well as a reduced risk of increased IOP. , department after accidentally instilling superglue into We present a case report of a patient with markedly his eyes. He had traditionally put eye drops in himself in elevated lOP associated with the use of 1% rimexolone the evening. On this occasion he had mistaken his wife's suspension. fingernail glue for the eye drops as it stood on the bedside cabinet. The bottles were very similar in reduced Case report light, as both were a dropper design for delivery and the same compact size. A 52-year-old woman with a history of toxic epidermal Once the glue, of which the major constituent was necrolysis has been attending our institution since 1992. cyanoacrylate, contacted his eye it caused immense As a result of her condition she developed dry eyes sudden pain causing him to close his eye more. The glue which required punctal occlusion and eye lubricants, then set quickly and thus he presented with a including autologous serum drops. She had marked permanently closed eye. The upper lid was adherent to keratinisation of the tarsal conjunctiva especially in the the cornea, as when the eye movements were tested the left eye, which necessitated mucous membrane grafting. lid moved. Her condition was further complicated by metaplastic He was followed up and after two consultations he eyelashes, which were treated with cryotherapy.
  • Pharmaceuticals As Environmental Contaminants

    Pharmaceuticals As Environmental Contaminants

    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
  • Pharmacy Program and Drug Formulary

    Pharmacy Program and Drug Formulary

    Pharmacy Program and Drug Formulary Secure Horizons Group Retiree Medicare Advantage Plan n Pharmacy Program Description n Platinum Plus Enhanced Formulary California Benefits Effective January 1, 2006 Table of Contents Your Secure Horizons Group Retiree Medicare Advantage Plan Prescription Drug Benefit........................................................................................................ iii Secure Horizons Pharmacy Program Definitions .................................................................... iii What Is the Platinum Plus Enhanced Formulary? ....................................................................iv Where to Have Your Prescriptions Filled .................................................................................iv Preferred and Non-Preferred Network Pharmacies .................................................................iv Network Preferred Pharmacy Locations ..................................................................................iv How to Fill a Prescription at a Network Pharmacy ...................................................................v Mail Service Pharmacy ..............................................................................................................v Secure Horizons Group Retiree Medicare Advantage Plan Offers a Two-Part Prescription Drug Benefit ..........................................................................vii Part 1 – Medicare Part D Prescription Drug Coverage ...................................................vii How Your Medicare
  • (12) United States Patent (10) Patent No.: US 7,544,192 B2 Eaton Et Al

    (12) United States Patent (10) Patent No.: US 7,544,192 B2 Eaton Et Al

    US007544192B2 (12) United States Patent (10) Patent No.: US 7,544,192 B2 Eaton et al. (45) Date of Patent: Jun. 9, 2009 (54) SINUS DELIVERY OF SUSTAINED RELEASE 5,443,498 A 8, 1995 Fontaine THERAPEUTICS 5,512,055 A 4/1996 Domb et al. 5,664,567 A 9, 1997 Linder (75) Inventors: Donald J. Eaton, Woodside, CA (US); 5,693,065. A 12/1997 Rains, III Mary L. Moran, Woodside, CA (US); 5,792,100 A 8/1998 Shantha Rodney Brenneman, San Juan Capistrano, CA (US) (73) Assignee: Sinexus, Inc., Palo Alto, CA (US) (Continued) (*) Notice: Subject to any disclaimer, the term of this FOREIGN PATENT DOCUMENTS patent is extended or adjusted under 35 U.S.C. 154(b) by 992 days. WO WOO1/02024 1, 2001 (21) Appl. No.: 10/800,162 (22) Filed: Mar 12, 2004 (Continued) (65) Prior Publication Data OTHER PUBLICATIONS US 2005/OO437O6A1 Feb. 24, 2005 Hosemann, W. et al. (Mar. 2003, e-pub. Oct. 10, 2002). “Innovative s Frontal Sinus Stent Acting as a Local Drug-Releasing System.' Eur: Related U.S. Application Data Arch. Otorhinolarynolo. 260:131-134. (60) Provisional application No. 60/454,918, filed on Mar. (Continued) 14, 2003. Primary Examiner Kevin C Sirmons (51) Int. Cl Assistant Examiner Catherine NWitczak A. iM sI/00 (2006.01) (74) Attorney, Agent, or Firm Morrison & Foerster LLP (52) U.S. Cl. ........................ 604/506; 604/510; 604/514 (57) ABSTRACT (58) Field of Classification Search .............. 604/93.01, 604/891.1. 890.1, 57, 59-64, 510, 514,506; S lication file f 606/196 The invention provides biodegradable implants for treating ee application file for complete search history.
  • LGC Standards Pharmacopoeial Reference Standards 2014

    LGC Standards Pharmacopoeial Reference Standards 2014

    LL CTS INKSP RODUTO A L P ITH W WEBSHO LGC Standards Pharmacopoeial reference standards 2014 FOR STANDARDS WITH CofA SEE OUR CATALOGUE: PHARMACEUTICAL IMPURITIES AND PRIMARY REFERENCE STANDARDS LGC Quality – ISO Guide 34 • GMP/GLP • ISO 9001 • ISO/IEC 17025 • ISO/IEC 17043 Pharmaceutical impurities Code Product CAS No. CS Price Unit Adiphenine Hydrochloride O LGC Standards N O MM1172.00 Adiphenine Hydrochloride 50-42-0 A 250mg HCl Pharmaceutical impurities and Adrenaline Tartrate OH H OH O OH primary reference standardsMM0614.00 2014 N OH Adrenaline Tartrate 51-42-3 A 500mg OH OH O OH OH H MM0614.02 L-Adrenaline 51-43-4 A 500mg OH N OH Imp. C (EP) as Hydrochloride: 1-(3,4-Di- O H OH MM0614.13 hydroxyphenyl)-2-(methylamino)ethanone 62-13-5 A 100mg N HCl Hydrochloride (Adrenalone Hydrochloride) OH (1R)-1-(3,4-Dihydroxyphenyl)-2- OH O S O MM0614.01 methylaminoethanesulphonic Acid H 78995-75-2 A 100mg OH N (Adrenaline -Sulphonate) OH Alanine NH2 MM0566.00 Alanine 56-41-7 A 500mg OH O Imp. A (Pharmeuropa): (2 S)-2-Aminobutanedioic Acid O NH 2 MM0567.00 OH (Aspartic Acid) 56-84-8 A 500mg OH O Albendazole O H MM0382.00 Albendazole N O 54965-21-8 A 500mg N H S N Imp. A (EP): 5-(Propylsulphanyl)-1H- H MM0382.01 N 80983-36-4 A 100mg NH2 benzimidazol-2-amine S N O H Imp. B (EP): Methyl [5-Propylsulphinyl)- N O MM0382.02 N 54029-12-8 A 100mg H 1H-benzimidazol-2-yl]carbamate S N O O H Imp.
  • Improved Penetrating Topical Pharmaceutical Compositions Containing Corticosteroids

    Improved Penetrating Topical Pharmaceutical Compositions Containing Corticosteroids

    Europaisches Patentamt ® European Patent Office © Publication number: 0 129 283 Office europeen des brevets A2 © EUROPEAN PATENT APPLICATION © Application number: 84200821.1 ©Int CI.3: A 61 K 31/57 A 61 K 47/00, A 61 K 9/06 © Date of filing: 12.06.84 © Priority: 21.06.83 US 506274 © Applicant: THE PROCTER & GAMBLE COMPANY 01.02.84 US 576065 301 East Sixth Street Cincinnati Ohio 45201 (US) © Date of publication of application: © Inventor: Cooper, Eugene Rex 27.12.84 Bulletin 84/52 2425 Ambassador Drive Cincinnati, OH 45231 (US) © Designated Contracting States: BE CH DE FR GB IT Li NL SE © Inventor: Loomans, Maurice Edward 5231 Jessup Road Cincinnati, OH 45239IUS) © Inventor: Fawzi, Mahdi Bakir 11 Timberline Drive Flanders New Jersey 07836(US) © Representative: Suslic, Lydia et al, Procter & Gamble European Technical Center Temselaan 100 B-1820 Strombeek-Bever(BE) © Improved penetrating topical pharmaceutical compositions containing corticosteroids. Topical pharmaceutical compositions containing a cor- ticosteroid component and a penetration-enhancing vehicle are disclosed. The vehicle comprises a binary combination of a C3-C4 diol and a "cell-envelope disordering compound". The vehicle provides marked transepidermal and percutaneous delivery of corticosteroids. A method of treating certain rheumatic and inflammatory conditions, systemically or loc- ally, is also disclosed. TECHNICAL FIELD The present invention relates to topical compositions effective in delivering high levels of certain pharmaceutically-active cor- ticosteroid agents through the integument. Because of the ease of access, dynamics of application, large surface area, vast exposure to the circulatory and lymphatic networks, and non-invasive nature of the treatment, the delivery of pharmaceutically-active agents through the skin has long been a promising concept.
  • Wo 2008/127291 A2

    Wo 2008/127291 A2

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 23 October 2008 (23.10.2008) WO 2008/127291 A2 (51) International Patent Classification: Jeffrey, J. [US/US]; 106 Glenview Drive, Los Alamos, GOlN 33/53 (2006.01) GOlN 33/68 (2006.01) NM 87544 (US). HARRIS, Michael, N. [US/US]; 295 GOlN 21/76 (2006.01) GOlN 23/223 (2006.01) Kilby Avenue, Los Alamos, NM 87544 (US). BURRELL, Anthony, K. [NZ/US]; 2431 Canyon Glen, Los Alamos, (21) International Application Number: NM 87544 (US). PCT/US2007/021888 (74) Agents: COTTRELL, Bruce, H. et al.; Los Alamos (22) International Filing Date: 10 October 2007 (10.10.2007) National Laboratory, LGTP, MS A187, Los Alamos, NM 87545 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY,BZ, CA, CH, (30) Priority Data: CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, 60/850,594 10 October 2006 (10.10.2006) US ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (71) Applicants (for all designated States except US): LOS LR, LS, LT, LU, LY,MA, MD, ME, MG, MK, MN, MW, ALAMOS NATIONAL SECURITY,LLC [US/US]; Los MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, Alamos National Laboratory, Lc/ip, Ms A187, Los Alamos, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, NM 87545 (US).
  • Drugs That May Be Used Based on Licensure Designation Page 1 of 7 Updated February 2021 by the Pennsylvania State Board of Optometry

    Drugs That May Be Used Based on Licensure Designation Page 1 of 7 Updated February 2021 by the Pennsylvania State Board of Optometry

    Drugs Which May Be Used Based on Licensure Designation Approved Drugs a.) Administration and prescription of pharmaceutical agents for therapeutic purposes. Optometrists who are certified to prescribe and administer pharmaceutical agents for therapeutic purposes under section 4.1 of the Optometric Practice and Licensure Act (63 P. S. § 244.4a), may prescribe and administer the drugs listed in subsections (c)(1) – (11) below in their practice of optometry. See also 49 Pa. Code § 23.202 for the application procedure for optometrists to administer and prescribe pharmaceutical agents for therapeutic purposes. b.) Administration and prescription of pharmaceutical agents to treat glaucoma. Optometrists who are certified to prescribe and administer pharmaceutical agents to treat glaucoma under section 4.2 of the Optometric Practice and Licensure Act (63 P.S. § 244.4b), may prescribe and administer the drugs listed in subsection (c)(12) below in their practice of optometry. See also 49 Pa. Code § 23.205 for the application procedure for optometrists to administer and prescribe pharmaceutical agents to treat glaucoma. c.) DEA registration reminder. Licensees who hold, or plan to obtain, a DEA registration are reminded to review and comply with PDMP standards. d.) Allowable pharmaceutical products. Optometrists may prescribe and administer the following pharmaceutical products or the A-rated generic therapeutically equivalent drug: (1) Topical Anesthetics (i) benoxinate (ii) lidocaine (iii) proparacaine (iv) tetracaine (2) Topical Ocular Lubricants